News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Leonhardt Ventures To Present Technology Showcase @ Heart Rhythm 2014


5/9/2014 8:25:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LOS ANGELES, May 8th, 2014 -- Heart Rhythm 2014 will be held in San Francisco, CA May 7th to 10th and Leonhardt Ventures' Cal-X Stars Business Accelerator will be holding a technology showcase and scientific advisory board meeting at the St. Regis Hotel, The Muse Boardroom Level 3, 125 3rd Street, San Francisco, CA 94103 from 3:30pm to 5:30pm on Friday, May 9th.

Companies and innovations to be showcased include:

MyoStim Pacers – http:/www.myostimpacers.com - world's first heart failure pacemaker with ability to recruit reparative stem cells to damaged and weakened heart tissue.

MyoStim Peripheral - electrical stimulation device for treating critical limb ischemia and diabetic foot ulcers.

Bioheart, Inc. – http://www.bioheartinc.com - Phase III leader in applying adult muscle stem cells to treat advanced heart failure. Only cell type known to grow new contractile muscle in the depths of scar tissue.

BioPace – world's first biological pacemaker made entirely of living cells.

CoroStim – world's first vibrational energy emitting pacemaker that prevents plaque formation in high risk coronary arteries. BioLeonhardt – http://www.bioleonhardt.com - first implantable, programmable, re-fillable stem cell pump in combination with electrical stimulation for treating advanced heart failure. Featuring combined utilization of MicroRNAs, time release SDF-1, various growth factors, nutrient hydrogel, cardiac stem cells, iPS cells and muscle progenitor stem cells all with repeat deliveries.

Cardiobridge – http://www.cardiobridge.com - Highest flow rate 10FR circulatory support catheter pump in clinical testing for acute decompensating heart failure and high-risk PCI. Data on about 30 clinical patients will be presented.

AortaCell – Method and device to treat aortic aneurysms non-invasively with an abdominal belt that delivers focal wireless electrical energy to weakened aortic wall tissue that causes reparative autologous stem cells to home to that chosen treatment location which are then differentiated into smooth muscle thus reinforcing vessel wall strength.

EndoCell – Method and device for growing new endothelium lining of a damaged artery with a percutaneous needle catheter and endothelial progenitor cells.

Valvublator – Percutaneous catheter device for de-calcifying and cell sodding heart valve leaflets so a patient may keep their own valve instead of getting an artificial implant.

HeartScore – Full line up of @ home heart health products, cardiovascular genetic tests and @ home monitoring -www.heartscore.co

About Leonhardt Ventures: Since 1982 Leonhardt Ventures www.leonhardtventures.com has a strong history of inventing, developing, backing and bringing to market leadership products for treating heart and cardiovascular disease. Over 200,000 patients have been treated to date with Leonhardt inventions. In the 1980's the group developed market leadership in patented polyurethane balloon catheters including drug, stem cell and radiation delivery systems and also turn-key cath labs and CCUs. In the 1990s they developed over 20 additional devices including the first commercially successful stent graft for aortic aneurysm repair (TALENT – Taheri-Leonhardt Stent Graft), the first percutaneous heart valve, intravascular lung catheter, the Pro-Cell intracavity stem cell delivery system and the MyoCath line of stem cell delivery catheters. Leonhardt patented inventions include the first heart failure pacemaker able to recruit reparative stem cells to damaged heart tissue (MyoStim Pacers). In 2001 the team led the first in the world non-surgical case of stem cell repair of damaged heart muscle in a human patient with Bioheart MyoCell. That led to the first Phase III double blinded, randomized, placebo controlled trial for stem cells growing new contractile muscle in post heart attack tissue in advanced heart failure patients – results published in the American Heart Journal Bioheart MyoCell pts 95.7 meters improvement in exercise capacity over placebo (minus 4 meters decline). The team is preparing to complete the first ever biological pacemaker implantation in a human patient within the next 12-18 months (BioPace).

About Cal-X Stars Business Accelerator, Inc: Leonhardt Ventures' organized the Cal-X Stars Business Accelerator, Inc.www.calxstars.com in 2013 to serve as a 5 year business accelerator for cardiovascular life science and social good impact innovations and startups.

Contact: Howard Leonhardt, Leonhardt Ventures, 1531 6th Street, Unit 401, Santa Monica, California, 90401, DIRECT phone 310 310 2534, email: hleonhardt@aol.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES